I. Smith

M. Dowsett, I. Smith, E. Arriola, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.

M. Dowsett, A. Harris, I. Smith, 1984, European journal of cancer & clinical oncology.

Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.

M. Dowsett, A. Harris, I. Smith, 1984, The Journal of clinical endocrinology and metabolism.

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

M. Dowsett, A. Harris, I. Smith, 1984, British Journal of Cancer.

Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.

M. Dowsett, A. Harris, I. Smith, 1983, British Journal of Cancer.

Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen.

K. Maclennan, M. Dowsett, J. Salter, 1994, European journal of cancer.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

T. Powles, M. Dowsett, P. Ellis, 2006 .

Oncogene Products and Other Diagnostic Markers in Human Breast Cancer Patients

T. Powles, M. Dowsett, P. Ellis, 1996, Annals of the New York Academy of Sciences.

Whole blood assay for assessment of the mixed lymphocyte reaction.

I. Smith, B. Souberbielle, R. Mendes, 2001, Journal of immunological methods.

The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.

M. Dowsett, A. Lal, I. Smith, 1987, British Journal of Cancer.

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

S. Johnston, M. O'Brien, A. Constantinidou, 2011, British Journal of Cancer.

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

S. Johnston, M. O'Brien, R. Jones, 2009, British Journal of Cancer.

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

M. Dowsett, C. Benz, G. Scott, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

M. Dowsett, J. Salter, S. Johnston, 1995, Cancer research.

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

M. Dowsett, S. Johnston, S. Jacobs, 1994, Cancer research.

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

M. Dowsett, S. Ebbs, J. Salter, 2001, Cancer research.

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

T. Aas, S. Geisler, P. Lønning, 1997, British Journal of Cancer.

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

M. Dowsett, S. Johnston, I. Smith, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration

M. Dowsett, M. Jarman, I. Smith, 1993, The Lancet.

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

M. Dowsett, A. Lal, I. Smith, 1989, British Journal of Cancer.

Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.

I. Taylor, D. Hedley, R. Stuart-Harris, 1985, British Journal of Cancer.

Biomarkers and predictive factors of response to neoadjuvant treatment

M. Dowsett, J. Salter, A. Dunbier, 2009, Breast Cancer Research.

Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.

M. Dowsett, A. Harris, J. Mckinna, 1982, The Journal of clinical endocrinology and metabolism.

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer

M. Dowsett, L. Zabaglo, R. A’Hern, 2012, British Journal of Cancer.

Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.

M. Dowsett, I. Smith, S. Johnston, 1995, Cancer research.

Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment

T. Powles, D. Collins, M. Leach, 1998, NMR in biomedicine.

Landfills: is wetter better?

M. Dowsett, A. Harris, R. Stuart-Harris, 1998, British Journal of Cancer.

Role of aminoglutethimide in male breast cancer.

M. Dowsett, A. Harris, R. Stuart-Harris, 1986, British journal of cancer.

Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer

M. Dowsett, S. Johnston, I. Smith, 1995, The Lancet.

Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer

M. Dowsett, M. Baum, B. Haynes, 1993, Breast Cancer Research and Treatment.

Aminoglutethimide dose and hormone suppression in advanced breast cancer.

M. Dowsett, A. Harris, I. Smith, 1983, European journal of cancer & clinical oncology.

Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer

M. Dowsett, S. Johnston, I. Smith, 1995 .

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.

M. Dowsett, A. Harris, R. A’Hern, 1995, British Journal of Cancer.

New treatments for advanced cancer: an approach to prioritization

I. Smith, S. Masters, I. Smith, 2000, British Journal of Cancer.

LOW-DOSE AMINOGLUTETHIMIDE AND AROMATASE INHIBITION

M. Dowsett, R. Santen, R. Stuart-Harris, 1985, The Lancet.

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

M. Dowsett, A. Harris, B. Cantwell, 1985, British Journal of Cancer.

Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer

G. Manikhas, J. Pierga, C. Thomssen, 2010 .

Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.

M. Dowsett, I. Smith, S. Jacobs, 1992, Clinical therapeutics.

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study

M. Dowsett, L. Zabaglo, A. Dodson, 2015, British Journal of Cancer.

Preoperative chemotherapy induces apoptosis in early breast cancer

M. Dowsett, P. Ellis, J. Salter, 1997, The Lancet.

Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223).

M. Dowsett, J. Mayordomo, J. Salter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

V. R. McCready, D. Jodrell, A. Irvine, 1988, British Journal of Cancer.

The concentration of 67Ga and 45Ca in the lactating mammary gland and its relevance to the tumor uptake of 67Ga citrate.

V. R. McCready, D. Taylor, A. Paterson, 1976, Cancer research.

LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER

M. Dowsett, I. Smith, J. Gazet, 1984, The Lancet.

Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer.

I. Smith, J. Teale, I. Smith, 1988, British Journal of Cancer.

Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

I. Smith, E. Moskovic, M. Seymour, 1997, British Journal of Cancer.

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

L. Assersohn, K. Last, D. Tait, 2006, British Journal of Cancer.

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

P. Ellis, M. Nicolson, D. Talbot, 1995, British Journal of Cancer.

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.

I. Smith, J. Hardy, I. Smith, 1989, British Journal of Cancer.

Cisplatin and its analogues in the treatment of advanced breast cancer: a review.

D. Talbot, I. Smith, D. Talbot, 1992, British Journal of Cancer.

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.

T. Powles, M. Dowsett, R. Coombes, 1996, British Journal of Cancer.

IN-VIVO 31P MAGNETIC RESONANCE SPECTROSCOPY FOR MONITORING TREATMENT RESPONSE IN BREAST CANCER

D. Collins, M. Leach, J. Mansi, 1989, The Lancet.

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

S. Ebbs, I. Smith, R. A’Hern, 1993, British Journal of Cancer.

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.

A. Graeff, M. Leach, I. Smith, 1991, British Journal of Cancer.

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

M. Dowsett, A. Harris, I. Smith, 1984, British Journal of Cancer.

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

H. Sinnett, J. Mansi, G. Walsh, 1991, British Journal of Cancer.

Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas.

M. Dowsett, P. Ellis, P. Mainwaring, 1998, Cytometry.